Nuvation Bio (NUVB) Return on Equity (2023 - 2025)
Nuvation Bio (NUVB) has disclosed Return on Equity for 3 consecutive years, with 0.65% as the latest value for Q4 2025.
- On a quarterly basis, Return on Equity rose 53.0% to 0.65% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.65%, a 53.0% increase, with the full-year FY2025 number at 0.53%, up 53.0% from a year prior.
- Return on Equity was 0.65% for Q4 2025 at Nuvation Bio, down from 0.62% in the prior quarter.
- In the past five years, Return on Equity ranged from a high of 0.11% in Q1 2024 to a low of 1.4% in Q3 2024.
- A 3-year average of 0.8% and a median of 0.65% in 2025 define the central range for Return on Equity.
- Biggest YoY gain for Return on Equity was 78bps in 2025; the steepest drop was -126bps in 2025.
- Nuvation Bio's Return on Equity stood at 0.12% in 2023, then plummeted by -843bps to 1.18% in 2024, then surged by 45bps to 0.65% in 2025.
- Per Business Quant, the three most recent readings for NUVB's Return on Equity are 0.65% (Q4 2025), 0.62% (Q3 2025), and 0.51% (Q2 2025).